From the Division of Neurosurgery (T.E.D., J.M.F., M.B.K., M.M.C.C., C.J.O.).
Service of Neurosurgery (M.W.B., C.C.).
AJNR Am J Neuroradiol. 2023 Jun;44(6):634-640. doi: 10.3174/ajnr.A7865. Epub 2023 May 11.
Surgical clipping and endovascular treatment are commonly used in patients with unruptured intracranial aneurysms. We compared the safety and efficacy of the 2 treatments in a randomized trial.
Clipping or endovascular treatments were randomly allocated to patients with one or more 3- to 25-mm unruptured intracranial aneurysms judged treatable both ways by participating physicians. The study hypothesized that clipping would decrease the incidence of treatment failure from 13% to 4%, a composite primary outcome defined as failure of aneurysm occlusion, intracranial hemorrhage during follow-up, or residual aneurysms at 1 year, as adjudicated by a core lab. Safety outcomes included new neurologic deficits following treatment, hospitalization of >5 days, and overall morbidity and mortality (mRS > 2) at 1 year. There was no blinding.
Two hundred ninety-one patients were enrolled from 2010 to 2020 in 7 centers. The 1-year primary outcome, ascertainable in 290/291 (99%) patients, was reached in 13/142 (9%; 95% CI, 5%-15%) patients allocated to surgery and in 28/148 (19%; 95% CI, 13%-26%) patients allocated to endovascular treatments (relative risk: 2.07; 95% CI, 1.12-3.83; = .021). Morbidity and mortality (mRS >2) at 1 year occurred in 3/143 and 3/148 (2%; 95% CI, 1%-6%) patients allocated to surgery and endovascular treatments, respectively. Neurologic deficits (32/143, 22%; 95% CI, 16%-30% versus 19/148, 12%; 95% CI, 8%-19%; relative risk: 1.74; 95% CI, 1.04-2.92; = .04) and hospitalizations beyond 5 days (69/143, 48%; 95% CI, 40%-56% versus 12/148, 8%; 95% CI, 5%-14%; relative risk: 0.18; 95% CI, 0.11-0.31; < .001) were more frequent after surgery.
Surgical clipping is more effective than endovascular treatment of unruptured intracranial aneurysms in terms of the frequency of the primary outcome of treatment failure. Results were mainly driven by angiographic results at 1 year.
手术夹闭和血管内治疗常用于颅内未破裂动脉瘤患者。我们在一项随机试验中比较了这两种治疗方法的安全性和有效性。
夹闭或血管内治疗随机分配给通过参与医生判断为可通过这两种方法治疗的 1 个或多个 3-25mm 的颅内未破裂动脉瘤的患者。该研究假设夹闭将使治疗失败的发生率从 13%降至 4%,主要复合终点定义为动脉瘤闭塞失败、随访期间颅内出血或 1 年后仍存在动脉瘤,由核心实验室裁决。安全性结局包括治疗后新出现的神经功能缺损、住院时间>5 天以及 1 年时的总体发病率和死亡率(mRS>2)。无盲法。
2010 年至 2020 年在 7 个中心共纳入 291 例患者。291 例患者中的 290 例(99%)可评估 1 年的主要结局,手术组 13 例(9%;95%CI,5%-15%)和血管内治疗组 28 例(19%;95%CI,13%-26%)达到该主要结局(相对风险:2.07;95%CI,1.12-3.83; =.021)。手术组和血管内治疗组 1 年时的发病率和死亡率(mRS>2)分别为 3/143(2%;95%CI,1%-6%)和 3/148(2%;95%CI,1%-6%)。神经功能缺损(32/143,22%;95%CI,16%-30% 与 19/148,12%;95%CI,8%-19%;相对风险:1.74;95%CI,1.04-2.92; =.04)和住院时间>5 天(69/143,48%;95%CI,40%-56% 与 12/148,8%;95%CI,5%-14%;相对风险:0.18;95%CI,0.11-0.31;<0.001)在手术后更为常见。
就治疗失败的主要结局发生率而言,手术夹闭治疗颅内未破裂动脉瘤比血管内治疗更有效。结果主要由 1 年时的血管造影结果驱动。